This Article Full Text Full Text (PDF) All Versions of this Article: 110/7/810    most recent 01.CIR.0000138929.71660.E0v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scheller, B. Articles by Nickenig, G. Search for Related Content PubMed PubMed Citation Articles by Scheller, B. Articles by Nickenig, G. Related Collections Restenosis Animal models of human disease Smooth muscle proliferation and differentiation Catheter-based coronary and valvular interventions: other

(Circulation. 2004;110:810-814.)
© 2004 American Heart Association, Inc.

Original Articles

Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis

Bruno Scheller, MD; Ulrich Speck, PhD; Claudia Abramjuk, DVM; Ulrich Bernhardt, PhD; Michael Böhm, MD; Georg Nickenig, MD

From the Department of Internal Medicine III—Cardiology/Angiology (B.S., M.B., G.N.), University of Saarland, Homburg/Saar, Germany; the Department of Radiology (U.S., C.A.), Charité University Hospital, Berlin, Germany; and Anakat GmbH (U.B.), Berlin, Germany.

Correspondence to Bruno Scheller, MD, Internal Medicine III (Cardiology/Angiology), University of Saarland, D 66421 Homburg/Saar, Germany. E-mail bruno.scheller{at}uniklinik-saarland.de

Received January 29, 2004; revision received May 4, 2004; accepted May 6, 2004.

Background— Drug-eluting stents have shown promising antirestenotic effects in clinical trials. Non–stent-based local delivery of antiproliferative drugs may offer additional flexibility and also reach vessel areas beyond the immediate stent coverage. The aim of the present study was to evaluate a novel method of local drug delivery based on angioplasty balloons.

Methods and Results— Stainless steel stents (n=40; diameter, 3.0 to 3.5 mm; length, 18 mm) were implanted in the left anterior descending and circumflex coronary arteries of domestic pigs. Both conventional uncoated and 3 different types of paclitaxel-coated, percutaneous transluminal coronary angioplasty balloons (contact with vessel wall for 1 minute) were used. No difference in short-term tolerance between coated and uncoated balloons and no signs of thrombotic events were observed. Quantitative angiography and histomorphometry of the stented arteries asserted the statistical equality of the baseline parameters between the control and the 3 treatment groups. Paclitaxel balloon coating led to a marked, dose-dependent reduction of parameters characterizing in-stent restenosis (reduction of neointimal area up to 63%). Despite the marked reduction in neointimal proliferation, endothelialization of stent struts was present in all samples. There was no evidence of a significant inflammatory response in the neighborhood of the stent struts.

Conclusions— Paclitaxel balloon coating is safe, and it effectively inhibits restenosis after coronary angioplasty with stent implantation in the porcine model. The degree of reduction in neointimal formation was comparable to that achieved with drug-eluting stents.

Key Words: restenosis • angioplasty • paclitaxel

This article has been cited by other articles:

				R. Waksman and R. Pakala Drug-Eluting Balloon: The Comeback Kid? Circ Cardiovasc Interv, August 1, 2009; 2(4): 352 - 358. [Full Text] [PDF]

				M. Unverdorben, C. Vallbracht, B. Cremers, H. Heuer, C. Hengstenberg, C. Maikowski, G. S. Werner, D. Antoni, F. X. Kleber, W. Bocksch, et al. Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis Circulation, June 16, 2009; 119(23): 2986 - 2994. [Abstract] [Full Text] [PDF]

				M. Werk, S. Langner, B. Reinkensmeier, H.-F. Boettcher, G. Tepe, U. Dietz, N. Hosten, B. Hamm, U. Speck, and J. Ricke Inhibition of Restenosis in Femoropopliteal Arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot Trial Circulation, September 23, 2008; 118(13): 1358 - 1365. [Abstract] [Full Text] [PDF]

				G. Tepe, T. Zeller, T. Albrecht, S. Heller, U. Schwarzwalder, J.-P. Beregi, M.D. C. D. Claussen, A. Oldenburg, B. Scheller, and U. Speck Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg N. Engl. J. Med., February 14, 2008; 358(7): 689 - 699. [Abstract] [Full Text] [PDF]

				B. Scheller, U. Speck, and M. Bohm Prevention of restenosis: is angioplasty the answer? Heart, May 1, 2007; 93(5): 539 - 541. [Abstract] [Full Text] [PDF]

				B. Scheller, C. Hehrlein, W. Bocksch, W. Rutsch, D. Haghi, U. Dietz, M. Bohm, and U. Speck Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter N. Engl. J. Med., November 16, 2006; 355(20): 2113 - 2124. [Abstract] [Full Text] [PDF]

				U. Speck, B. Scheller, C. Abramjuk, C. Breitwieser, J. Dobberstein, M. Boehm, and B. Hamm Neointima Inhibition: Comparison of Effectiveness of Non-Stent-based Local Drug Delivery and a Drug-eluting Stent in Porcine Coronary Arteries. Radiology, August 1, 2006; 240(2): 411 - 418. [Abstract] [Full Text] [PDF]